The three major myeloproliferative syndromes are polycythemia vera, idiopathic myelofibrosis, and essential thrombocytosis. All are clonal disorders of hematopoietic stem cells and all are associated with a mutation in the JAK2 kinase (V617F) that results in activation of the kinase. The mutation is seen in 90% of pts with polycythemia vera and ∼45% of pts with idiopathic myelofibrosis and essential thrombocytosis.

There's more to see -- the rest of this topic is available only to subscribers.